Member Services - PRO MEDICUS LTD- PME.ASX
2024/11/07
Pro Medicus (PME) share price is at $200, what’s driving the share price?
PME has demonstrated consistent performance, maintaining healthy earnings growth and return on equity (ROE) over the past several years. The company has strategically acquired contractors in the U.S., its largest revenue market. With no debt, a strong base of repeat customers, and an emerging focus on artificial intelligence, PME is well-positioned for future growth. This trajectory has instilled significant confidence among investors, resulting in the company trading at an extraordinary price-to-earnings (P/E) ratio of 250.
https://youtu.be/Bl7iRYdClTw
Pro medicus - update 2024/10/07
PME secures a 8 year, $96 M, contract
Pro Medicus has secured long-term contracts, like the recent $96 million renewal in the U.S., which highlights its ability to retain and expand business with large healthcare providers. This provides a solid revenue base and increases the likelihood of further international expansion, particularly in the U.S., where healthcare systems are increasingly relying on advanced imaging technologies like Pro Medicus' Visage software.
https://youtu.be/hTQxFIH9vg8
Important disclaimer:
These posts/articles were written without taking into account your objectives, needs, or financial situation, and they do not constitute financial advice nor a buy/sell/hold recommendation. Therefore, you should consult a financial advisor and determine whether the information mentioned in these posts/articles is appropriate for your financial circumstances, goals, and needs before acting on it. While every reasonable attempt has been made to ensure the correctness of the information shared, we cannot guarantee its accuracy, completeness, or currency. No legal responsibility is assumed for any mistakes or omissions, whether they were made intentionally or not. Read the full disclaimer